Amphastar (AMPH) | Financial Analysis & Statements
Amphastar Pharmaceuticals Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
183.1M
Gross Profit
85.7M
46.79%
Operating Income
35.6M
19.45%
Net Income
24.4M
13.34%
Balance Sheet Metrics
Total Assets
1.6B
Total Liabilities
840.5M
Shareholders Equity
788.8M
Debt to Equity
1.07
Cash Flow Metrics
Operating Cash Flow
37.6M
Free Cash Flow
24.6M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Amphastar Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 719.9M | 732.0M | 644.4M | 499.0M | 437.8M |
| Cost of Goods Sold | 363.8M | 358.1M | 293.3M | 250.1M | 238.0M |
| Gross Profit | 356.1M | 373.9M | 351.1M | 248.9M | 199.7M |
| Gross Margin % | 49.5% | 51.1% | 54.5% | 49.9% | 45.6% |
| Operating Expenses | |||||
| Research & Development | 85.8M | 73.9M | 73.7M | 74.8M | 60.9M |
| Selling, General & Administrative | 129.8M | 94.5M | 80.4M | 66.6M | 68.9M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 215.7M | 168.4M | 154.1M | 141.4M | 129.9M |
| Operating Income | 140.4M | 205.4M | 197.0M | 107.5M | 69.9M |
| Operating Margin % | 19.5% | 28.1% | 30.6% | 21.5% | 16.0% |
| Non-Operating Items | |||||
| Interest Income | 8.7M | 10.6M | 5.5M | 1.3M | 601.0K |
| Interest Expense | 25.5M | 30.3M | 27.2M | 1.8M | 885.0K |
| Other Non-Operating Income | 23.0K | 4.1M | -3.9M | 9.1M | 14.5M |
| Pre-tax Income | 123.6M | 189.8M | 171.4M | 116.0M | 84.1M |
| Income Tax | 25.5M | 29.7M | 31.8M | 23.5M | 20.6M |
| Effective Tax Rate % | 20.7% | 15.6% | 18.6% | 20.2% | 24.5% |
| Net Income | 98.1M | 159.5M | 137.5M | 91.4M | 63.3M |
| Net Margin % | 13.6% | 21.8% | 21.3% | 18.3% | 14.5% |
| Key Metrics | |||||
| EBITDA | 212.3M | 277.3M | 240.3M | 146.2M | 111.6M |
| EPS (Basic) | $2.10 | $3.29 | $2.85 | $1.88 | $1.30 |
| EPS (Diluted) | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 |
| Basic Shares Outstanding | 46743000 | 48429000 | 48265000 | 48551000 | 47777000 |
| Diluted Shares Outstanding | 46743000 | 48429000 | 48265000 | 48551000 | 47777000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Amphastar Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 170.2M | 151.6M | 144.3M | 156.1M | 126.4M |
| Short-term Investments | 112.6M | 70.0M | 112.5M | 19.7M | 10.3M |
| Accounts Receivable | 143.6M | 136.3M | 114.9M | 88.8M | 78.8M |
| Inventory | 176.9M | 153.7M | 105.8M | 103.6M | 92.8M |
| Other Current Assets | 13.2M | 18.2M | 9.1M | 7.6M | 7.3M |
| Total Current Assets | 636.0M | 534.1M | 489.6M | 378.3M | 318.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 43.2M | 47.3M | 32.9M | 26.3M | 27.2M |
| Goodwill | 569.4M | 593.7M | 616.5M | 40.4M | 42.2M |
| Intangible Assets | 562.6M | 587.6M | 610.1M | 34.2M | 35.6M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 73.6M | 97.1M | 79.2M | 59.4M | 39.1M |
| Total Non-Current Assets | 993.3M | 1.0B | 1.0B | 363.7M | 353.4M |
| Total Assets | 1.6B | 1.6B | 1.5B | 742.0M | 671.5M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 32.6M | 30.5M | 25.4M | 20.5M | 22.2M |
| Short-term Debt | 9.6M | 7.0M | 4.3M | 6.0M | 5.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 158.2M | 173.8M | 225.4M | 94.9M | 103.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 646.4M | 643.5M | 619.3M | 96.5M | 99.5M |
| Deferred Tax Liabilities | 5.9M | 7.0M | 6.1M | 7.4M | 7.1M |
| Other Non-Current Liabilities | 30.0M | 20.9M | 22.7M | 14.6M | 15.7M |
| Total Non-Current Liabilities | 682.3M | 671.4M | 648.1M | 118.5M | 122.2M |
| Total Liabilities | 840.5M | 845.2M | 873.5M | 213.3M | 226.0M |
| Equity | |||||
| Common Stock | 6.0K | 6.0K | 6.0K | 6.0K | 6.0K |
| Retained Earnings | 666.9M | 568.8M | 409.3M | 271.7M | 180.3M |
| Treasury Stock | 408.1M | 332.7M | 247.4M | 189.5M | 150.5M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 788.8M | 732.3M | 639.4M | 528.7M | 445.5M |
| Key Metrics | |||||
| Total Debt | 656.0M | 650.5M | 623.6M | 102.6M | 104.7M |
| Working Capital | 477.9M | 360.3M | 264.2M | 283.5M | 214.3M |
Balance Sheet Composition
Amphastar Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 98.1M | 159.5M | 137.5M | 91.4M | 63.3M |
| Depreciation & Amortization | 63.2M | 57.2M | 41.8M | 28.3M | 26.5M |
| Stock-Based Compensation | 27.3M | 24.4M | 20.2M | 17.9M | 18.7M |
| Working Capital Changes | -62.4M | -3.8M | -21.5M | -30.3M | -4.9M |
| Operating Cash Flow | 157.1M | 226.3M | 175.7M | 91.9M | 108.1M |
| Investing Activities | |||||
| Capital Expenditures | -34.9M | -41.0M | -38.2M | -23.6M | -27.5M |
| Acquisitions | 0 | -129.0M | -506.4M | 0 | 0 |
| Investment Purchases | -119.1M | -76.8M | -144.6M | -35.8M | -17.4M |
| Investment Sales | 90.3M | 126.0M | 38.6M | 28.0M | 18.8M |
| Investing Cash Flow | -68.1M | -124.9M | -649.1M | -32.8M | -28.7M |
| Financing Activities | |||||
| Share Repurchases | -75.6M | -85.5M | -58.1M | -39.9M | -28.9M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 6.2M | 18.4M | 845.0M | 0 | 70.0M |
| Debt Repayment | -223.0K | -8.3M | -318.7M | -1.8M | -37.9M |
| Financing Cash Flow | -70.3M | -76.1M | 443.1M | -42.1M | -54.1M |
| Free Cash Flow | 119.0M | 172.3M | 145.3M | 65.1M | 70.5M |
| Net Change in Cash | 18.8M | 25.3M | -30.3M | 17.0M | 25.3M |
Cash Flow Trend
Amphastar Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
10.34
Forward P/E
6.18
Price to Book
1.24
Price to Sales
1.32
PEG Ratio
-0.31
Profitability Ratios
Profit Margin
13.63%
Operating Margin
19.45%
Return on Equity
12.90%
Return on Assets
6.37%
Financial Health
Current Ratio
4.02
Debt to Equity
83.16
Beta
0.91
Per Share Data
EPS (TTM)
$2.07
Book Value per Share
$17.28
Revenue per Share
$15.40
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AMPH | 953.5M | 10.34 | 1.24 | 12.90% | 13.63% | 83.16 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| Dynavax Technologies | 1.8B | 54.60 | 3.41 | -7.14% | -13.13% | 54.15 |
| Ani Pharmaceuticals | 1.8B | 24.08 | 3.10 | 16.16% | 8.87% | 116.19 |
| Perrigo Company plc | 1.6B | 2,818.00 | 0.55 | -38.66% | -33.51% | 131.16 |
Financial data is updated regularly. All figures are in the company's reporting currency.






